ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC) for AMGEN
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
- Puerto Rico tax incentives
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN E IRIZARRY | — |
| VINCENT A. ROBERTI, SR. | — |
Health Issues HCR
- Issues related to biosimilars, generally; Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (S. 974/H.R. 2212) - Issues related to drug pricing and value, generally - Issues related to the importation of prescription medicines, including the Affordable and Safe Prescription Drug Importation Act (H.R. 1245/S. 469); and the Improving Access to Affordable Prescription Drugs Act (H.R. 1776/S. 771) - Issues involving the Federal, Food, Drug and Cosmetic Act (FFDCA)
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN E IRIZARRY | — |
| VINCENT A. ROBERTI, SR. | — |
Medicare/Medicaid MMM
- Issues related to Medicare Part B (Average Sales Price) - Issues related to Medicare Part D - Coding and reimbursement for oncology drugs/biologics/biosimilars - Issues relating to the 340B Drug Pricing Program, including the 340B Protecting Access for the Underserved and Safety-Net Entities (PAUSE) Act (H.R. 4710); the Helping Ensure Low-income Patients have Access to Care and Treatment (HELP) Act (S. 2312); the Ensuring the Value of the 340B Program Act (S. 2453), and the 340B Optimization Act (H.R. 5598) - Issues related to the repeal of the Independent Payment Advisory Board (IPAB); Protecting Seniors' Access to Medicare Act of 2017 (H.R. 849/S. 260); Protecting Medicare from Executive Action Act of 2017 (S. 251)
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN E IRIZARRY | — |
| VINCENT A. ROBERTI, SR. | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.